|Bid||52.76 x 100|
|Ask||52.81 x 600|
|Day's range||52.74 - 54.15|
|52-week range||16.95 - 63.60|
|PE ratio (TTM)||N/A|
|Earnings date||19 Feb 2018 - 23 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||58.63|
Jim Cramer lifted the hood on Tesla’s move higher and why he thinks the stock rose despite fewer-than-expected Model 3 deliveries in Q4.
Investors attending the conference want to know if companies are planning more M&A in the wake of tax reform. Pricing practices also could be in focus.
Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, today announced that it has appointed Stanley Lapidus to the role of independent board member on its Board of Directors. Lapidus has more than 30 years’ experience in the medical diagnostics industry as a founder, CEO and board member at companies that have dramatically impacted the diagnostics landscape, including his founding of EXACT Sciences Corp. (NASDAQ:EXAS) and, prior to that, Cytyc Corp., which was sold to Hologic Corporation in 2007. “We are honored to have Stan, a true luminary in biotechnology, join Atlas Genetics as its newest board member,” said Jeff Luber, President and CEO of Atlas.
Investors in the cancer detection company have enjoyed a phenomenal run recently, but where is this business heading in the next half-decade?
Exact Sciences (EXAS) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.
Citron Research's Andrew Left, who gained notoriety for successful bets against companies such as Valeant, posted a bearish report on Exact Sciences.
In an interview on CNBC's "Fast Money," Kevin Conroy clashes with Andrew Left over the analysis of the company.